Brief: Monte Rosa Therapeutics Presents Preclinical Data From Gspt1 Degrader Program Focused On Myc-Driven Cancers At Aacr 2023
17/04/2023 22:49
April 17 (Reuters) - Monte Rosa Therapeutics Inc
GLUE.O :
* MONTE ROSA THERAPEUTICS PRESENTS PRECLINICAL DATA FROM
GSPT1
DEGRADER PROGRAM FOCUSED ON MYC-DRIVEN CANCERS AT AACR 2023
* MONTE ROSA THERAPEUTICS INC - PHASE 1/2 CLINICAL TRIAL OF
MRT-2359 ONGOING IN MYC-DRIVEN SOLID TUMORS, INCLUDING LUNG
CANCER
* MONTE ROSA THERAPEUTICS INC - DISCLOSURE OF INITIAL DATA
FROM
PHASE 1 ARM OF STUDY EXPECTED IN SECOND HALF OF 2023
Source text for Eikon: ID:nGNX4LC0v1
Further company coverage: GLUE.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Monte Rosa Therapeutics
See all newsBrief: Monte Rosa Therapeutics Announces Positive Results For Mrt-8102 In Gforce-1 Phase 1 Study Showing Normalization Of Key Pathogenic Drivers Of Ascvd In Subjects With Elevated Cvd Risk
Brief: Monte Rosa Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Monte Rosa Therapeutics, Inc. reports results for the quarter ended June 30 - Earnings Summary
Monte Rosa Therapeutics Q2 revenue drops, net loss widens on higher R&D
Brief: Monte Rosa Therapeutics Q2 Collaboration Revenue USD 8.968 Million